Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summit’s Global Phase III Development Program Starts with Initiation of HARMONi-GI3 ...
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated ...
“We continue to operate with financial discipline, focusing our resources on advancing our cell therapy programs toward the clinical stage,” said Sanjeev Luther, President and CEO of Ernexa ...
Fortrea reported third-quarter revenue of $701 million, up 4% from the prior-year period. Management raised its 2025 revenue guidance by 283 basis points at the midpoint and maintained the midpoint of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback